JW Pharmaceutical Corp Total Liabilities
JW Pharmaceutical Corp total liabilities. Based on the latest financial reports, JW Pharmaceutical Corp (001067) has total liabilities worth ₩257.46 Billion KRW (≈ $174.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check JW Pharmaceutical Corp (001067) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of JW Pharmaceutical Corp (2014–2024)
Total liabilities of JW Pharmaceutical Corp from 2014 to 2024. This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. Explore JW Pharmaceutical Corp long-term investment allocation to see how much of total assets are deployed in long-term investments.
JW Pharmaceutical Corp Competitors by Total Liabilities
The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bon Natural Life Ltd
NASDAQ:BON
|
USA | $27.19 Million |
|
JPMorgan European Growth & Income plc
LSE:JEGI
|
UK | GBX42.04 Million |
|
Data Storage Corp
NASDAQ:DTST
|
USA | $1.03 Million |
|
Burford Capital Limited
LSE:BUR
|
UK | GBX3.50 Billion |
|
PT Mitra Pack Tbk
JK:PTMP
|
Indonesia | Rp104.19 Billion |
|
Hube Yangfan Holding Co Ltd
SHG:600421
|
China | CN¥191.69 Million |
|
Diamond Estates Wines & Spirits Inc
V:DWS
|
Canada | CA$23.76 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of JW Pharmaceutical Corp.
Liquidity & Leverage Metrics
JW Pharmaceutical Corp Total Liabilities Ratios Explained
JW Pharmaceutical Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩275.11 Billion ≈ $186.44 Million |
-27.53% |
| 2023-12-31 | ₩379.60 Billion ≈ $257.25 Million |
-5.62% |
| 2022-12-31 | ₩402.21 Billion ≈ $272.57 Million |
-9.52% |
| 2021-12-31 | ₩444.51 Billion ≈ $301.24 Million |
+30.12% |
| 2020-12-31 | ₩341.62 Billion ≈ $231.51 Million |
-0.44% |
| 2019-12-31 | ₩343.12 Billion ≈ $232.52 Million |
+2.83% |
| 2018-12-31 | ₩333.68 Billion ≈ $226.13 Million |
-7.34% |
| 2017-12-31 | ₩360.10 Billion ≈ $244.03 Million |
-3.91% |
| 2016-12-31 | ₩374.76 Billion ≈ $253.97 Million |
-3.43% |
| 2015-12-31 | ₩388.07 Billion ≈ $262.99 Million |
+5.11% |
| 2014-12-31 | ₩369.22 Billion ≈ $250.21 Million |
-- |
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more